CAR T cell therapy has achieved durable clinical responses in patients with CD19-expressing refractory and relapsed B cell malignancies and CD269 (B-cell maturation antigen (BCMA))-expressing multiple myeloma cells and is increasingly investigated as a therapeutic option of other malignancies (97). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.